Patient with Resistant Hypertension

  • Julian Segura
Part of the Practical Case Studies in Hypertension Management book series (PCSHM)


A 68-year-old, Caucasian male was referred by his family physician for assessment of uncontrolled arterial hypertension. He is treated with three antihypertensive drugs. 24-h ambulatory blood pressure monitoring (ABPM) was performed, and the final diagnosis was true resistant hypertension.

The definition of resistant hypertension is based on office blood pressure (BP) measurements. ABPM is mandatory in resistant hypertensive patients to define true and white-coat resistant hypertension, as the latter group has a better prognosis.


Resistant hypertension 24-h ambulatory blood pressure monitoring Cardiovascular risk High blood pressure Spironolactone 


  1. 1.
    Williams B, Mancia G, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. J Hypertens. 2018;39(33):3021–104.Google Scholar
  2. 2.
    Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71:2199–269.CrossRefGoogle Scholar
  3. 3.
    Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403–19.CrossRefGoogle Scholar
  4. 4.
    Siddiqui M, Dudenbostel T, Calhoun DA. Resistant and refractory hypertension: antihypertensive treatment resistance vs treatment failure. Can J Cardiol. 2016;32:603–6.CrossRefGoogle Scholar
  5. 5.
    de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57:898–902.CrossRefGoogle Scholar
  6. 6.
    Pierdomenico SD, Lapenna D, Bucci A, Di Tommaso R, Di Mascio R, Manente BM, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens. 2005;18:1422–8.CrossRefGoogle Scholar
  7. 7.
    Redon J, Campos C, Narciso ML, Rodicio JL, Pascual JM, Ruilope LM. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension. 1998;31:712–8.CrossRefGoogle Scholar
  8. 8.
    Segura J, Ruilope LM. Resistant hypertension. In: Lerma EV, Rosner MH, Perazella MA, editors. Current diagnosis & treatment: nephrology & hypertension. 2nd ed. New York: McGraw-Hill Education; 2018.Google Scholar
  9. 9.
    de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension. 2010;5(5):147–52.CrossRefGoogle Scholar
  10. 10.
    Alvarez-Alvarez B, Abad-Cardiel M, Fernandez-Cruz A, Martell-Claros N. Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system. J Hypertens. 2010;28:2329–35.CrossRefGoogle Scholar
  11. 11.
    Segura J, Cerezo C, Garcia-Donaire JA, Schmieder RE, Praga M, de la Sierra A, et al. Validation of a therapeutic scheme for the treatment of resistant hypertension. J Am Soc Hypertens. 2011;5:498–504.CrossRefGoogle Scholar
  12. 12.
    Vaclavik J, Sedlak R, Plachy M, Navratil K, Plasek J, Jarkovsky J, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57:1069–75.CrossRefGoogle Scholar
  13. 13.
    Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059–68.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Julian Segura
    • 1
  1. 1.Hypertension Unit, Department of NephrologyHospital Universitario 12 de OctubreMadridSpain

Personalised recommendations